TPV staging

Heartflow (HTFL) reported FISH&CHIPS results at AHA 2025, showing AI-driven Plaque Analysis and total plaque volume (TPV) staging predict long-term coronary risk. In nearly 8,000 symptomatic patients, the highest TPV stage had a hazard ratio of 5.10 for major cardiovascular events. DECIDE registry data showed management changes with a LDL reduction of 18.7 mg/dL at 90 days. Plaque Staging is investigational; Plaque Analysis is FDA-cleared.